Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This train has left the station. The CEO should be getting swamped with calls. My average unfortunately is about $1.76
What this company has done since the Fall...https://www.newsfilecorp.com/release/77429/ScreenPro-Provides-Corporate-Update
You might want to follow G6 Materials GPHPF and GGG.
Dave at Bare Oaks Ontario.
PR Aug. 22, 2019
https://theralase.com/pressrelease/theralase-announces-closing-of-prospectus-offering-for-gross-proceeds-of-17250000/
It's estimated that these funds are enough to complete Phase II over the next 2 years. No more share dilution is expected.
A million 7 in first half and near a million in past 3 months in gross sales. That's an increase in 42.9% in 3 months.
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
V.TLT | 8 days ago
TORONTO, ON / ACESSWIRE / May 20, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Company has been granted a Notice of Acceptance by the Chinese patent office for PDCs.
The patent entitled, "Metal-Based Thiophene Photodynamic Compounds and Their Use" advances Theralase's intellectual property portfolio internationally and permits the Company to expand Theralase's advanced PhotoDynamic Therapy ("PDT") technology in the Chinese market, subject to Chinese regulatory approvals. The patent encompasses an extensive library of PDCs, including Theralase's lead PDC, TLD-1433, recently Health Canada Clinical Trial Authorization ("CTA") and Investigational Testing Authorization ("ITA") approved to be evaluated in a pivotal Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study.
China is the most populated country in the world, with an estimated population of 1.4 billion 1.
Annual revenue of the oncology drug market in China was approximately $USD 20 billion in 2017 and is expected to grow to $USD 38 billion by 2022 and $USD 95 billion by 2030 2.
The incidence and mortality rates of bladder cancer continue to increase annually in China, predominantly in urban areas, with approximately 74% of bladder cancer diagnoses in China classified as NMIBC 3.
Dr. Shawn Shirazi, CEO-Drug Division, Theralase stated, "I am delighted that Theralase continues to expand its international intellectual property portfolio, providing additional barriers to entry for the Company's Anti-Cancer Therapy ("ACT") platform, both in medical device technology and in PDCs. This notice of acceptance represents the advancement of a strategic objective of the Company; namely, providing layers of protection of the intellectual property rights of the Company's ACT in major medical markets. China is one of those major medical markets. Pending successful achievement of efficacy and safety endpoints in the Phase II ACT-NMIBC study and required regulatory approval, China, among other major medical markets; including: Canada, the United States and the European Union, are getting in line for use of this advanced PDT technology in the treatment of patients diagnosed with Bacillus Calmette Guérin ("BCG")-Unresponsive NMIBC. Theralase is committed to developing innovative ACT technology and introducing them as quickly and humanely as possible to the expanding global oncology market."
1 U.S. Census Bureau Current Population [Internet]. Census.gov. 2019 [cited 16 May 2019]. Available from: https://www.census.gov/popclock/print.php?component=counter
2 Research and Markets. China Monoclonal Antibody (PD-1,CD20,HER2,VEGF,EGFR,TNF-a) Market, 2018-2025: Characteristics and Significance of Drugs Procurement with Target Quantity [Internet]. GlobeNewswire. 2019 [cited 16 May 2019]. Available from: https://www.globenewswire.com/news-release/2019/01/15/1691560/0/en/China-Monoclonal-Antibody-PD-1-CD20-HER2-VEGF-EGFR-TNF-a-Market-2018-2025-Characteristics-and-Significance-of-Drugs-Procurement-with-Target-Quantity.html
3 Cheng Pang, Youyan Guan, Hongbo Li, Wanqing Chen, Gang Zhu, Urologic cancer in China, Japanese Journal of Clinical Oncology, Volume 46, Issue 6, June 2016, Pages 497-501, https://doi.org/10.1093/jjco/hyw034
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.
Additional information is available at www.theralase.com and www.sedar.com
This news release contains "forward-looking statements" which reflect the current expectations of the Company's management of future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com ). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
1.866.THE.LASE (843-5273) x 304
416.699.LASE (5273) x 304
Amelia Tudo, Investor Relations Coordinator
atudo@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
June 30th, 2018
Theralase® Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study based on successfully achieving its primary and secondary endpoints after six patients.
Toronto, Ontario – May 30, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer has successfully completed the Study.
On May 19, 2018, Theralase’s Medical and Scientific Advisory Board (“MSAB”) was convened to examine the clinical results obtained on the first six patients enrolled and treated in the Study utilizing TLD-1433-based Photo Dynamic Therapy (“PDT”); specifically: the primary endpoint of safety and tolerability, the secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and the exploratory endpoint of efficacy primarily at 90 days.
The MSAB is comprised of world-renowned experts in bladder cancer and have been retained by the Company to provide advice and strategic guidance on the research, development and commercialization of the TLD-1433-based PDT technology in the treatment of patients inflicted with NMIBC.
After reviewing the clinical data presented by Girish Kulkarni, MD, PhD, FRCSC, an Associate Professor at the University of Toronto, Department of Surgery and the Principal Investigator of the Study, the MSAB unanimously recommended the early termination of the Study due to achievement of the primary and secondary endpoints. The MSAB also recommended that the clinical data collected from the first three patients treated at the Maximum Recommended Starting Dose (“MRSD”) (0.35 mg/cm2) and the three patients treated at the Therapeutic Dose (0.70 mg/cm2) were sufficient to support the conclusion that the Study had successfully achieved the Study’s primary and secondary endpoints and had adequately addressed the Study’s scientific, technical and clinical questions, as per the approved Study design and clinical protocol. The MSAB recommendation to the Company was to terminate the Study based on the six patients treated to date and suggested that the Company pursue a pivotal Phase II NMIBC clinical study approval with Health Canada and the FDA with efficacy as the primary endpoint.
Dr. Kulkarni stated that, “The primary and secondary endpoints of the Study have been successfully accomplished from a clinical aspect. The treatment was safe and well tolerated by all patients treated, with no discernible difference in the number or severity of Adverse Events (“AEs”), regardless of whether the MRSD or Therapeutic Dose was utilized. All AEs were either minor (Grade 1) or moderate (Grade 2) in severity and completely resolved within 90 days. There were no severe (Grade 3), life threatening (Grade 4) or deaths (Grade 5) AEs and the majority of AEs were transient and related to irritative lower urinary tract symptoms (i.e.: urination urgency). TLD-1433 systemic absorption was minimal (picograms concentration in plasma), which is magnitudes below the No Observed Adverse Effect Level (“NOAEL”) for TLD-1433 and hence presents no significant clinical risk. I believe that TLD-1433 holds real potential as a treatment for NMIBC and I look forward to treating patients in a pivotal Phase II NMIBC clinical study, pending Health Canada approval to commence the study.
Michael Jewett, MD, FRCSC, FACS, Professor of Surgery (Urology) at the University of Toronto and the Chairman of Theralase’s MSAB stated that, “When NMIBC intravesical treatment with Bacillus Calmete Guérin (“BCG”) fails, the standard of care is cystectomy (removal of the patient’s bladder), which is a major surgery with life-altering side effects that many patients may not accept despite the risk of cancer spread. The Study clinical data presented by Dr. Kulkarni is very encouraging. TLD-1433 PDT appears safe and well-tolerated in patients presenting with BCG-Unresponsive NMIBC. I am pleased that the clinical results of the Study met its objectives demonstrating that the Theralase PDT technology has demonstrated potential as a treatment for bladder cancer. The MSAB members and I unanimously support the view that the Study achieved its primary and secondary endpoints after the treatment of 6 patients and concluded that the clinical data collected supports an early termination of the Phase I Study to commence a pivotal Phase II NMIBC clinical study focused on efficacy. The Phase II NMIBC study design has been discussed and collectively approved during the MSAB meeting. The exploratory endpoint of efficacy is extremely encouraging as the fifth and sixth patients are clinically cancer free as of the ninety day cystoscopy examination.”
Ashish Kamat, MD, MBBS, Professor of Urologic Oncology (Surgery) and Wayne B. Duddlesten Professor of Cancer Research, University of Texas, MD Anderson Cancer Center stated that, “The safety data presented by Dr Kulkarni and Theralase is convincing and recruitment of an additional three patients at the Therapeutic Dose is not likely to add significant value to the understanding of the PDT technology in the treatment of NMIBC. If a larger multicenter study demonstrates efficacy of PDT technology in this patient population, it would provide our patients a useful alternative to avoid radical surgery. The more safe, reliable options we have to offer our patients, the better it is for everyone concerned. The MSAB thus recommended that the Company truncate the Study early to seek Health Canada and FDA approval to commence a larger and more statistically powered, single arm, multicenter efficacy study. Moreover, the MSAB reviewed and approved in principle the Phase II clinical protocol and the clinical study design presented by Dr. Jewett. BCG-Unresponsive NMIBC is a potentially fatal disease that requires additional treatment options. Currently, cystectomy remains the safest treatment option available to patients, but if the Theralase PDT achieves its efficacy endpoint in a Phase II clinical study, then this will present patients with an attractive additional treatment option. The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.”
Michael O’Donnell, MD, Professor of Urology, University of Iowa, Iowa City, Iowa stated, “I’m encouraged by the Theralase Phase Ib clinical study data presented at the MSAB meeting. The top-line clinical results indicate that the TLD-1433-based PDT at tested doses has met its primary and secondary objectives in the studied population of BCG-Unresponsive patients with NMIBC who refused cystectomy. The Theralase approach is an interesting treatment option with an early signal of treatment effectiveness, albeit in a small population, that will need to be confirmed in a Phase II clinical study. This is a novel approach that addresses a bladder cancer population with a high unmet need. As designed, a successful Phase II clinical study will confirm how this PDT therapy approach could shape future practice.”
About the Study
The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.
Study Outcome Endpoints:
1) Primary: Evaluate safety and tolerability. (Measured by patients who experience Adverse Events (“AEs”) Grade 4 or greater that do not resolve within thirty (30) days; whereby: Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life-threatening or disabling AE, Grade 5 = Death)
2) Secondary: Evaluate the pharmacokinetics. (movement and exit of drug within tissue) of TLD-1433 (Measured by TLD-1433 concentration levels in plasma and urine over 72 hours.)
3) Exploratory: Evaluate efficacy. (Measured by Recurrence Free Survival (“RFS”), defined as the interval from Day 0 (Day of PDT treatment) to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e.: any biopsy-confirmed new or recurrent tumour), evaluated at 90 days for the first three patients treated at the MRSD and primarily at 90 days for the last six patients treated at the Therapeutic Dose and secondarily at 180 days post treatment)
The Company is planning to meet with Health Canada and FDA, to discuss and finalize the design of a Health Canada and FDA pivotal Phase II NMIBC clinical study, with a primary endpoint of efficacy.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers. The Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.
Additional information is available at www.theralase.com and www.sedar.com
Welcome to Theralase Technologies Inc.
Developing Photo Dynamic Compounds.
Planning Stage II for Bladder Cancer trial.
Planning Stage I for Brain Cancer trial.
Latest info in response to my email to David regarding current status and future plans...(Still R&D to do)
Hi Dave
There's interest in the nanoparticle technology from some companies (licensing and/or a joint venture to make pouch cells) and I'm working on that more than anything. The companies I've spoken to (believe it or not, I can't say how many of them there are -- a long and silly NDA story) want to see it perform in ~100mAh, 1Ah, 3Ah and 20Ah configurations.
Another company, separate from the ones that want to see the technology in pouch cells, approached us and, if things continue to go well I will have a face to face with them in a couple months.
If a deal of some kind is made, I don't think it will happen before the new year. What the deal will be (e.g., license, JV, us depositing particles on their stuff, etc.) is up in the air right now, but I imagine they would want to license it.
David
Yes, I can get it and chart it on TD. Did not sell this time. Dave
I moved on to stocks like SWY, NSP, TLT and holding on to KWG.
Themes are diamonds, hemp protein, cancer cure and chromite, respectively.
Dave
MACD shows potential reversal or continued side movement at this point.
Possible use of IDs...
insert-text-here
If this chart repeats itself, keep an eye out, no time to hibernate. (g) Display since 2009 inception.
Dave
Is this new ETF going to seem like an IPO?
What SP would be your guess?
Dave
Watch out for a price run up before the report release, imho.
If there is a minor manipulation, it would come at the end of the day. Someone or company is biasing the prices upward by buying 100 to 500 shares in the last hour of a slow day. There is a company involved in promoting EIPC and I wonder if they are the ones trying their best to bias EIPC up higher with these late day trades to the ask price.
Re Buy Sell columns...
Usually IHub treats the second half of the trade as a BUY, if it matches an pre-existing higher Ask(will sell at) price OR the trade will be listed as a SELL if it is matched to an pre-existing lower Offer(will buy at) price.
Imho, Dave
New ultra cap apps.
Was at the home show today and noticed a guy selling retail and commercial constant night lights without typical batteries that uses ultra cap technology developed in S.Korea and distributed by someone in Oklahoma. Lights for highways, pathways, etc,.
I asked the seller if this S.Korean company was into RFIDs and he said no.
EIPC, you better hurry up. (g)
Dave F.
SC,
Please delete railroad post. Meant to go to KWG on Stockhouse.com
Dave F.
Building a railway on Permafrost
A Finnish young engineer takes a look how the problems were overcome...for now. Although high altitude problems were overcome, the future effects of global warming will be experienced in Northern Ontario, a much more sensitive area.
The recent highs hit resistence at the 200 day Moving Average line which means we should see consolidation (sideways) price action for a few weeks. Still time to scoop some sub cent buys on limit orders. imho. Dave
What about an order that's at a price between the bid and ask? Anyway, it's not terribly important to me.
Dave
Sure, but the order of orders placed determines whether it's registered as a Buy or Sell. The latest order, should determine what column it should appear. I just expect consistency and given how everything is automated and computerized, I was just surprised they don't follow a consistent pattern. Now I know better. (g)
Dave
Trade listing not always accurate. I just put in an additional 20,000 to buy and the trade was executed at 12:20pm but the Trades board shows it as a SELL. ?? Not that it matters a whole lot. (g)
Dave
Shelf Life
This item appears at the bottom of the Frick spec sheet if you use the link provided in the pinned message at the top of the messages section.
They post that Shelf Life is 2 years.
How are we supposed to differenciate ourselves from the rest of the pack if we can only advertise 2 years. There is no mention of the 7 year warranty either.
Dave (in Toronto)
Promoting our product.
In the Toronto Star, I happened to notice an ad by the Region of Peel to outfit RFIDs to waste collection programs.
Here is the lastest list of venders who have downloaded the requirements for starting a 12 month testing period.
In my spare time, I could call these companies and suggest checking the website of Enable and the new distributer for the Americas.
https://www.peelregion.ca/scripts/finance/biddocs.pl
Dave
Is there a board where one could post a list of cutting edge companies and their developements?
Dave
Zenn visits EEStor, leading edge in car batteries.
Look them up. Engaging information for those following this story.
Dave
Update: Zenn visits EEStor
September 12, 2012 - 6:35 PM EDT
ZENN Motor Company Provides Update on EEStor
TORONTO, ONTARIO--(Marketwire - Sept. 12, 2012) - ZENN Motor Company Inc. (TSX VENTURE:ZNN) ("ZENN" or the "Company") provided an update on EEStor Inc. ("EEStor") and its progress in the development of its Electrical Energy Storage Units ("EESUs"). This update is being made in connection with the commitment of ZENN to report on technological progress at EEStor by September 12, 2012 and in lieu of a direct release by EEStor. On September 10, 2012 representatives of ZENN and its consultant (Mr. John Galvagni, an expert in capacitors with extensive industry experience in energy storage) attended at the facilities of EEStor in Cedar Park, Texas. The ZENN team was given unprecedented access to EEStor and its technology. EEStor provided an in-depth briefing on the history of its development of EESUs and allowed ZENN's team to observe testing on various layers produced by EEStor.
EEStor is producing EESU layers in its facility in Cedar Park, Texas. The ZENN team was given a full tour of the state of the art facility. It observed a recently produced layer which was tested at 1 volt and had an observed permittivity level in excess of 100,000. The layer did not contain any of EEStor's proprietary composition-modified barium titanate ("CMBT") powders and so was not tested at higher voltages. Without the CMBT powders dissipation and leakage would not be expected to be at commercially acceptable levels. EEStor then demonstrated a layer produced some time ago which had an earlier version of its plastic based matrix and contained the CMBT powders. The earlier versions of the layer had substantially lower levels of permittivity than the recent layers. This layer with the CMBT had a permittivity of approximately 1000 and was tested at several voltages ranging from 1 volt to 1250 volts. There was no observed decline in permittivity throughout the test. Further, observed leakage throughout the test was not in excess of 1 micro ampere even at 1250 volts, a field of 50 volts/micron.
Mr. Galvagni has provided his preliminary report to ZENN and notes the following:
the level of permittivity achieved in the layers without CMBT is unprecedented and appears to represent a significant breakthrough in dielectric materials
the fact that permittivity of the layer with CMBT was maintained across a broad voltage range is a positive achievement as to date higher permittivity dielectric materials have shown significant declines in permittivity as voltage is increased. Declines are generally observable above permittivity levels of 50. Dielectric materials with a permittivity above 600 have all shown material declines in permittivity as voltage is increased. While the tested layer at a permittivity of 1000 is a long way from the 100,000 level in the current layers, it is a positive indicator of the performance of EESU layers where the CMBT has been added and is an important technological step. It remains to be seen whether the layers will maintain their permittivity when voltage is increased at permittivity levels well in excess of 1000
the consistency and characteristics of the CMBT appear to be at a level of purity not previously attained. Original purity levels were previously certified by EEStor through a third party in 2009.
the observed leakage rates are extremely compelling for energy storage applications
the plant employs advanced technologies and appears to be easily scalable
Overall Mr. Galvagni expressed his excitement in what he saw. Mr Galvagni was informed of the trigger in certain options granted on September 12, 2011 that depends on EEStor showing "significant progress in technology development" and was asked to provide independent advice in this regard. He advised ZENN that he had witnessed very significant technological progress in the area of capacitors, dielectrics and energy storage. He indicated that if high permittivity levels can be maintained across a range of voltages when the CBMT powders are added to the current polymer based high permittivity version of the EESU, the layers will have significant commercial potential. If the observed high permittivity can be maintained as voltage is increased it could be possible to produce high energy density layers at voltages much lower than the targeted 3500 volt level which would simplify the EESU's commercial application.
EEStor is now working on its next step of adding CMBT powders to its new polymer based high permittivity layers. It believes, based on fundamental research and the tests it provided to ZENN, that these layers should be able to achieve high energy density with low levels of dissipation and leakage and overall performance at or above the targets agreed with ZENN in the Technology Agreement between the parties dated May 15, 2012. However, until the layers are produced and tested there can be no assurance of the performance of these layers.
Jim Kofman Chairman and Interim CEO of ZENN commented: "This is the kind of information shareholders have been seeking for a long time. It is exciting to finally see the technological progress at EEStor. The EEStor team has been working long and hard to prove its technologies and was able to convincingly demonstrate some major achievements. We are mindful that the next step of producing layers that meet all our performance targets is the most critical step, but our observations and Mr. Galvagni's report give us the most current empirical evidence of major scientific breakthroughs at EEStor. It supports our confidence that things are going in the right direction and that EEStor has been making important breakthroughs."
To assist EEStor in its working capital needs, ZENN has offered to advance up to $200,000 to EEStor against payments payable under the milestones in the Technology Agreement subject to certain adjustments depending on when EESUs are certified.
Further updates will be provided once EEStor has produced and adequately tested its new layers. The observations from this visit do not constitute formal certification as ZENN was not able to test or calibrate the testing equipment and Mr. Galvagni was not engaged to conduct formal certification. An independent testing firm is expected to conduct such tests.
John Galvagni has worked in the technology space with a focus on capacitors and energy storage for over 50 years. Most importantly for 38 years he worked with AVX Corporation as an R&D Scientist and an AVX Fellow and was involved in the development of energy storage capacitors. He has an undergraduate degree in Chemistry from St. Michaels College, Vermont, did graduate work in Physics at Bennington College, Vermont and Mass State and an MBA from Webster University, Missouri.
About ZENN Motor Company Inc.
The Company's goal is to be the provider of leading edge power storage solutions and related technologies to the automotive industry.
Technologies and solutions, powered by EEStor's electrical energy storage units (EESU) have the potential to enable OEM and Tier 1 partners to deliver advanced electric transportation solutions to their customers.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: Marketwire Canada (September 12, 2012 - 6:35 PM EDT)
News by QuoteMedia
On Tuesday, there was an Ask at 0.0137 late in the day. How could the market jump over 137 to 16? without showing a fill at the 137 level. Just a technical question. I'm not complaining of course. (g)
DCHT seems to have gone private since it's no longer trading on NASDAQ or they moved off shore. Off Topic.
Dave
Was that your bid that got filled for 160K shares @ .02 ?
Dave
Bab, We already had a pull back March 28th to the 50 day moving average line on a rising moving average line. With upcoming positive news, there is no reason to expect another deep pull back to .02 cents, imho.
SC, one has to shell out the big bucks to be a subscriber to see your blog. I would like to make some money on my bet first. (g)
Dave
Told Dad and he 'bet' $300 for 12,000. (He used to be a handicaper) EIPC is a racehorse to him. (g)
Are we seeing a break up here? Not confirmed yet though with no news. The market likes to anticipate good news and we may see a pop, so when there is good news, the price stalls and slides down. We'll see soon enough. I'm set.
Dave in Toronto, Canada.
I wonder now about their burn rate and how much money is in the kitty. That should tell us how long they have left without refinancing resulting in stalling or downsizing the SP.
Dave
Whoa Ted. I thought the horse was first. Who else to pull the wagon of sales money? They have just introduced the product, it has to be evaluated, not to see if they work, but to see if there is a good application of the product to solve certain problems. Then the purchasing companies have to form and get approved a budget to pay for the product, then decide when to make the purchase. Time is needed for all those steps and probably many more steps as well. Just a guess. (g)
Dave in Toronto